GCIA
BHVN

Gabelli & Co Investment Advisers’s Biohaven Pharmaceutical Holding Company Ltd. BHVN Stock Holding History

Gabelli & Co Investment Advisers’s Portfolio BHVN Stock Details BHVN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-71,362
Closed -$10.8M – 501
2022
Q3 		$10.8M Sell
71,362
-28,638
-29% -$4.24M 1.4% 22
2022
Q2 		$14.6M Buy
+100,000
New +$12.8M 1.88% 11

Other funds holding BHVN

LIP
Liontrust Investment Partners London, United Kingdom $5.86B AUM 23.75% 1-Year Est. Return
KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
BC
Birchview Capital Burlington, Vermont $176M AUM 95.04% 1-Year Est. Return
BTI
Blue Trust Inc Alpharetta, Georgia $9.54B AUM 19.86% 1-Year Est. Return
FIA
FNY Investment Advisers New York $278M AUM 98.99% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
MSCM
McElhenny Sheffield Capital Management Dallas, Texas $404M AUM 19.8% 1-Year Est. Return

Gabelli & Co Investment Advisers's BHVN Position: Q4 2022 in Review

Gabelli & Co Investment Advisers sold out of Biohaven Pharmaceutical Holding Company Ltd. (BHVN) in Q4 2022, closing a stake of 71,362 shares — an estimated $10.8M sold.

Gabelli & Co Investment Advisers first reported a position in BHVN in Q2 2022 and held it in 2 quarters. The position peaked at $14.6M in Q2 2022. 7 funds tracked by Wall St. Rank hold BHVN as of Q4 2022.

  • Gabelli & Co Investment Advisers reported no remaining Biohaven Pharmaceutical Holding Company Ltd. position as of Q4 2022 after selling out during the quarter.
  • Gabelli & Co Investment Advisers sold 71,362 Biohaven Pharmaceutical Holding Company Ltd. shares in Q4 2022, an estimated $10.8M.
  • Gabelli & Co Investment Advisers first reported a position in Biohaven Pharmaceutical Holding Company Ltd. in Q2 2022 and held it in 2 quarters.
  • Gabelli & Co Investment Advisers's Biohaven Pharmaceutical Holding Company Ltd. position peaked at $14.6M in Q2 2022.
  • 7 funds tracked by Wall St. Rank held Biohaven Pharmaceutical Holding Company Ltd. as of Q4 2022.

Based on Gabelli & Co Investment Advisers's 13F filing for Q4 2022, filed 13 Feb 2023.